We are thrilled to present an insightful new article co-authored by Dr. Yurii Moroz, detailing a groundbreaking study that focused on the prostaglandin E2 receptor 4 (EP4R) and discovered a new way to treat inflammatory pain.

This approach has the potential to replace traditional NSAIDs, which are known for their side effects such as gastrointestinal issues and heart risks. Researchers screened over 400 million compounds, leading to a potent and selective EP4R antagonist. This compound, with its 16 nanomolar potency, shows promise in preclinical mouse models, demonstrating both anti-inflammatory and pain-relief properties. 

This advancement represents a significant step forward in the quest for more effective and safer pain management methods.

If you are keen to explore more about this fascinating research and dive into Chemspace research world, follow the link!